HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, August...
Patent extends HeartBeam's ECG hardware platform with multi-modal sensing capabilities Acoustic sensors enable HeartBeam’s device to function as a “digital...
Cardiac monitoring is evolving beyond the routine detection of abnormal heart rhythms toward a future where patients and physicians receive timely actionable insights that can guide clinical decisions...
HeartBeam (NASDAQ: BEAT) announced it has completed patient enrollment ahead of schedule in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The study enrolled 120...
Accelerated enrollment completion in ALIGN-ASS study underscores HeartBeam’s execution on its key strategic priority of heart attack detection Data analysis is underway, with...
HeartBeam (NASDAQ: BEAT) announced a strategic reorganization aimed at accelerating execution, expanding global market reach and improving capital efficiency as it advances commercialization of its cardiac...
Company will license its 3D ECG signal technology to established partners, moving beyond direct medical device sales Advancing toward heart attack detection...
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs....
HeartBeam (NASDAQ: BEAT) a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced that a peer-reviewed article in JACC: Advances demonstrated...
Insiders are betting big on three stocks. Board members, CEOs, and CFOs are among the buyers, signalling confidene in their fundamentals.